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Abstract
Background: Small heterodimer partner (SHP, NR0B2) is involved in diverse metabolic pathways, including hepatic bile
acid, lipid and glucose homeostasis, and has been implicated in effects on the peroxisome proliferator-activated
receptor γ (PPARγ), a master regulator of adipogenesis and the receptor for antidiabetic drugs thiazolidinediones (TZDs).
In this study, we aim to investigate the role of SHP in TZD response by comparing TZD-treated leptin-deficient (ob/ob)
and leptin-, SHP-deficient (ob/ob;Shp−/−) double mutant mice.
Results: Both ob/ob and double mutant ob/ob;Shp−/− mice developed hyperglycemia, insulin resistance, and
hyperlipidemia, but hepatic fat accumulation was decreased in the double mutant ob/ob;Shp−/− mice. PPARγ2 mRNA
levels were markedly lower in ob/ob;Shp−/− liver and decreased to a lesser extent in adipose tissue. The TZD
troglitazone did not reduce glucose or circulating triglyceride levels in ob/ob;Shp−/− mice. Expression of the
adipocytokines, such as adiponectin and resistin, was not stimulated by troglitazone treatment. Expression of hepatic
lipogenic genes was also reduced in ob/ob;Shp−/− mice. Moreover, overexpression of SHP by adenovirus infection
increased PPARγ2 mRNA levels in mouse primary hepatocytes.
Conclusions: Our results suggest that SHP is required for both antidiabetic and hypolipidemic effects of TZDs in ob/ob
mice through regulation of PPARγ expression.
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Background
Obesity is associated with cardiovascular disease, type 2
diabetes mellitus and some cancers [1,2]. Among these,
type 2 diabetes mellitus is a major source of mortality in
the obese population. Diabetes develops in the context
of both insulin resistance and β- cell dysfunction [3]. In
insulin resistance, the ability of insulin to enhance glu-
cose disposal in muscle and adipose tissue and to de-
crease gluconeogenesis in liver is impaired. Diabetes
ensues when the pancreatic β-cell cannot compensate
for insulin resistance by adequately increasing insulin
secretion.
Thiazolidinediones (TZDs) are a class of antidiabetic
drugs that act by increasing insulin sensitivity [4,5]. TZDs,
including troglitazone, rosiglitazone and pioglitazone,
improve insulin action in patients and a number of
insulin-resistant obese and diabetic murine models,
such as ob/ob (leptin-deficient), db/db (leptin receptor-
deficient), KKAy mice and Zucker fatty rats [6-8].
TZDs are potent agonist ligands for the nuclear hor-
mone receptor peroxisome proliferator-activated re-
ceptor γ (PPARγ) and their antidiabetic actions are
believed to be mediated by interactions with PPARγ
[9,10]. PPARγ is a key regulator of adipogenesis [11,12]
that exists as two protein isoforms, PPARγ1 and γ2,
arising from differential promoter usage. PPARγ2 en-
codes 30 additional amino acids at the N-terminus
compared to PPARγ1. PPARγ2 is expressed at highest
levels in adipose tissue compared to other major insu-
lin target tissues, such as liver and muscle, whereas
PPARγ1 is expressed at relatively low levels in many
tissues [11,13]. The expression pattern suggests that
adipose tissue is the primary target of TZD-induced
insulin sensitization as generally supported by tissue-
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specific PPARγ knockout studies, although other tissues
and cell types also contribute [14-18]. PPARγ expression
levels can change under different physiological condi-
tions and affect the response to TZD treatment [13].
For example, hepatic PPARγ expression is elevated in
animals that develop fatty livers [18-20], and increased
PPARγ2 expression is correlated with increased liver
fat in human subjects with non-alcoholic fatty liver
disease (NAFLD) [21]. TZD effects could be amplified
in such PPARγ-rich fatty livers, which may be particu-
larly relevant for the beneficial effects of TZD treatment
in human patients with non-alcoholic steatohepatitis
(NASH) [22,23].
Mutations in the small heterodimer partner (SHP,
NR0B2) have been associated with mild obesity in several
human populations [24-27]. SHP is an atypical orphan
nuclear receptor that lacks a conventional DNA-binding
domain [28,29]. Although SHP interacts with several
nuclear receptors by acting as a repressor [28,30-32], it
has been reported to increase the transcriptional activa-
tion of PPARγ [33]. In addition, hepatic PPARγ gene
expression is upregulated in transgenic mice expressing
SHP in the liver, suggesting that SHP may affect PPARγ
expression at the transcription level [34].
To investigate the role of SHP in TZD response in
obese diabetic mice, we compared glucose metabolism
and lipid profiles in ob/ob and ob/ob;Shp−/− double mu-
tant mice after TZD treatment. Troglitazone did not
reduce glucose or circulating triglyceride levels in the
ob/ob;Shp−/− mice, which showed markedly decreased
PPARγ expression in liver and, to a lesser extent, adi-
pose tissue. Furthermore, SHP overexpression increased
PPARγ mRNA levels in primary hepatocytes. These re-
sults suggest that SHP is required for TZD effects in




Shp−/− mice were generated previously in this laboratory
with a mixed C57BL/129sv hybrid background [35].
They were backcrossed to C57BL/6 J mice for 10 gener-
ations to obtain >99.99% pure C57BL/6 J background.
The leptin-deficient ob/ob and ob/ob;Shp−/− mice were
generated as described previously [36]. Groups of 10–15
male ob/ob and ob/ob;Shp−/− mice (7- to 8-week-old)
were oral gavaged with vehicle (10% dimethylsulfoxide
(DMSO) in corn oil) or troglitazone (Cayman chemical,
dissolved in DMSO, 10 mg/kg/day) for two weeks. Be-
fore the first day of treatment and on the day before
sacrifice, mice were fasted overnight and blood samples
were collected from the orbital plexus. Livers and white
adipose tissue were dissected, weighed and fixed for
histological analysis, or snap frozen in liquid nitrogen
and stored at −80°C until use. Mice were maintained in
the accredited pathogen-free facility at Baylor College of
Medicine on a 12-hour light/dark cycle and fed a stand-
ard rodent chow and water ad libitum. All protocols for
animal use were approved by the animal care committee
of Baylor College of Medicine.
Histological analysis
Livers were fixed, dehydrated and embedded in paraffin.
Sections were cut with a thickness of 5 μm and stained
with Harris hematoxylin-eosin (Sigma).
Serum and tissue chemistry
Serum was prepared from whole blood and stored at −80°C
until use. Lipids were extracted from liver using
chloroform-methanol extraction [37]. Enzymatic assay
kits were used for the determination of non-esterified
fatty acids (Wako), cholesterol and triglyceride (Thermo
Electron). Insulin levels were measured by a mouse/rat
insulin ELISA kit (Millipore-Linco).
Glucose tolerance test
Glucose tolerance tests (GTT) were performed by intra-
peritoneal injection of glucose (2 g/kg of body weight)
following overnight fasting. Blood samples were taken
at 0, 15, 30, 60, 120 minutes from the tail vein and were
analyzed for glucose concentrations using kits from
Thermo Electron.
RNA isolation and real-time quantitative PCR
Total RNA was isolated using TRIzol reagent (Invitro-
gen). 1 μg of total RNA was reverse transcribed using
QuantiTect Reverse Transcription kit (Qiagen) according
to manufacturer’s instructions. Real-time quantitative PCR
(SYBR green) analysis was performed on an ABI prism
7700 sequence detection system (Applied Biosystems)
under factory default thermal cycling conditions (50°C,
2 min; 95°C, 10 min; and 40 cycles at 95°C, 15 s; 60°C,
1 min). Expression was normalized to 36B4 and the rela-
tive quantification was calculated using ΔΔCt formula.
Primary hepatocyte isolation, culture and adenoviral
transduction
Primary hepatocytes were prepared from 8- to 12-week-
old wild type mice by in situ perfusion and single-step
Percoll gradient centrifugation [35]. Cells were plated at
106 per 6-cm dish and grown in Williams’ E medium
supplemented with 10 μg/ml transferrin, 10 μg/ml insu-
lin, 100U/ml penicillin and 100 μg/ml streptomycin.
One day after plating, the cells were infected with a
SHP-expressing adenovirus or a control virus expressing
GFP as described [38] for two hours at a multiplicity of in-
fection (MOI) of 20. Virus-containing media were removed
and cells were cultured for two days after infection. Total
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RNA were isolated from cells for real-time quantitative
PCR analysis.
Statistical analysis
Values are presented as means ± SEM. Statistical signifi-
cance was determined by two-tailed t test or ANOVA,
as appropriate.
Results
Troglitazone does not improve the diabetic syndromes in
ob/ob;Shp−/− mice
The ob/ob mouse is a valuable type 2 diabetes model.
Based on the role of the orphan nuclear receptor SHP
in metabolic pathways, we generated ob/ob;Shp−/− double
mutant mice. The obesity of the double mutants was not
different from the ob/ob mice (9-10-week-old ob/ob;Shp−/−
body weight 38.38 ± 1.9 g versus ob/ob 35.8 ± 1.7 g). We
initially assessed the effects of SHP deficiency on glucose
homeostasis by measuring blood glucose and insulin levels.
Glucose levels of ob/ob;Shp−/− mice were significantly
higher than those of ob/ob mice, whereas the insulin level
was markedly lower (Figure 1A, B). To further characterize
glucose metabolism, glucose tolerance tests were per-
formed and ob/ob;Shp−/− mice were more glucose-
intolerant compared to ob/ob mice (Figure 1C). These
results suggest that SHP deficiency aggravates hyper-
glycemia and insulin resistance in ob/ob mice, which is
quite different from the improvements previously de-
scribed [36]. The basis for this marked discrepancy is
not clear.
To test whether TZDs are effective in ob/ob;Shp−/−
mice with severe glucose intolerance, both ob/ob and
ob/ob;Shp−/− mice were treated with troglitazone for
2 weeks. As expected, the ob/ob mice showed dramatic-
ally lower serum glucose and insulin levels, as well as
improved glucose tolerance (Figure 1). In contrast, nei-
ther the serum glucose and insulin levels nor the glucose
tolerance was improved in the ob/ob;Shp−/− mice. These
results indicate that SHP is required for antidiabetic ef-
fects of TZDs in ob/ob mice.
Troglitazone has no effect on the lipid profile of
ob/ob;Shp−/− mice
Since SHP is normally highly expressed in the liver, we
further investigated the potential effects of SHP defi-
ciency in the ob/ob fatty liver. While the body weight
showed no significant difference between ob/ob and ob/
ob;Shp−/− mice, the liver weight of ob/ob;Shp−/− mice
was significantly lower than that of ob/ob mice, result-
ing in a smaller liver/body weight ratio (9-10-week-old
ob/ob;Shp−/− liver weight 1.67 ± 0.17 g versus ob/ob
2.12 ± 0.18 g, P < 0.05) (Figure 2B). Histological analysis
of the liver showed that lipid droplets were much
smaller and less numerous in ob/ob;Shp−/− mice than
that in ob/ob mice, indicating an improvement of fatty
liver in ob/ob;Shp−/− mice (Figure 2A), and this was con-
firmed by measuring hepatic triglycerides (Figure 2C).
These results are consistent with those described previ-
ously [36]. Troglitazone treatment of ob/ob mice caused
a significant increase in liver/body weight ratio and hep-
atic triglyceride content (Figure 2B and C). Histological
results also revealed that the size and number of lipid
droplets were increased by troglitazone treatment in ob/
ob mice (Figure 2A). However, these effects of troglita-
zone were not observed in ob/ob;Shp−/− mice. In addition,
the serum triglyceride- and FFA-lowering actions of trogli-
tazone observed in the ob/ob mice were absent in ob/
ob;Shp−/− mice (Figure 2D and E). These results confirm
that SHP is involved in the development of fatty liver in
ob/ob mice and is required for hypolipidemic effects of
TZDs.
SHP deficiency downregulates the expression of lipogenic
genes in ob/ob mice liver
Since hepatic PPARγ has been reported to play a critical







































Figure 1 SHP deficiency causes non-responsiveness to antidiabetic
effect of TZDs. (A, B) Serum glucose (A) and insulin (B) levels under
fasting conditions. 7–8 week-old male ob/ob and ob/ob;Shp−/− mice
were treated with control (open bars) or troglitazone (filled bars) for
2 weeks. (C) Glucose tolerance tests. Intraperitoneal glucose tolerance
tests were performed on ob/ob and ob/ob;Shp−/− mice treated with
control (open symbols) or troglitazone (filled symbols) for 2 weeks.
n = 4–5 per group. Data are mean ± SEM. *P < 0.05, **P < 0.01,
***P < 0.001 for differences between control and troglitazone-treated
ob/ob mice. #P < 0.01 for differences between ob/ob;Shp−/− (with no
effect of troglitazone treatment) and control-treated ob/ob mice.
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PPARγ1 and γ2 expression was examined in wt, Shp−/−, ob/
ob and ob/ob;Shp−/− mice (Figure 3A). The low basal
PPARγ1 levels showed about a 3-fold increase in both ob/
ob and ob/ob;Shp−/− mice compared to wt mice, but
PPARγ2 levels exhibited dramatic differences between ob/
ob and ob/ob;Shp−/− mice: a 40-fold increase in ob/ob mice
relative to wild type, but only a 5-fold increase in ob/
ob;Shp−/− mice.
To further define the genes regulated by SHP in the





















































Figure 2 SHP deficiency blunts TZD effects on lipid profile of ob/ob
mice. (A) Histology of livers from ob/ob and ob/ob;Shp−/− mice treated
with control or troglitazone for 2 weeks. H&E staining was performed
for liver sections. ×100 magnification. (B-E) 7–8 week-old male ob/ob
and ob/ob;Shp−/− mice were treated with control (open bars) or
troglitazone (filled bars) for 2 weeks. (B) Ratio of liver weight to body
weight (n = 10–15 per group). (C) Liver triglyceride (TG) content was
determined in liver extracts of ob/ob and ob/ob;Shp−/− mice (n = 4–5
per group). (D, E) Serum TG and free fatty acid (FFAs) contents under
fasting conditions (n = 10–12 and n = 4–5 per group, respectively). Data
are mean ± SEM. *P < 0.01, **P < 0.05, for differences within each
genotype between control and troglitazone-treated mice. #P < 0.01,










































































































Figure 3 Expression of lipogenic genes was downregulated by SHP
deficiency in ob/ob mice liver. Results in panels A and B are liver
mRNA levels for control (open bars) and troglitazone-treated (filled
bars) mice after 2 weeks of treatment. Data are expressed as relative
fold change after normalized to 36B4 and are mean± SEM (n= 4–5 per
group). By two-way ANOVA, the genotype effect (ob/ob and ob/ob;Shp−/−)
is significant (P < 0.05) for all except PPARγ1 in panel A. The treatment
effect and genotype × treatment interaction is significant for CD36,
aP2, FAS, ACC1 and PEPCK in panel B.
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hepatic triglyceride in ob/ob;Shp−/− mice, mRNA from
livers of control- and troglitazone-treated mice was an-
alyzed (Figure 3B). mRNA levels of fatty acid translo-
case (CD36), fatty acid synthase (FAS), adipocyte fatty
acid-binding protein (aP2), acetyl-CoA carboxylase 1
(ACC1) and stearoyl-CoA desaturase-1 (SCD-1) were
lower in ob/ob;Shp−/− mice than in ob/ob mice. Troglita-
zone treatment induced the expression of CD36, FAS,
aP2 and ACC1 mRNA in ob/ob mice, but not in ob/
ob;Shp−/− mice. There was no difference between ob/ob
and ob/ob;Shp−/− mice for expression of transcription fac-
tors regulating the lipogenic genes, such as SREBP-1c
and C/EBPα . The mRNA levels of genes associated with
glucose homeostasis, such as phosphoenolpyruvate car-
eboxykinase (PEPCK) for gluconeogenesis, were in-
creased in ob/ob;Shp−/− mice (Figure 3B), which may
partly account for the high blood glucose levels in these
double mutant mice (Figure 1A). The action of troglita-
zone to lower glucose levels in type 2 diabetics by de-
creasing gluconeogenesis in liver was observed in ob/ob
mice, but not in ob/ob;Shp−/− mice.
In summary, expression of lipogenic genes was decreased
by SHP deficiency in ob/ob mice, which has also been
observed in Western diet fed Shp−/− mice [39]. Con-
sistent with the low expression of hepatic PPARγ2 in
ob/ob;Shp−/− mice, functional response to PPARγ agon-
ist, troglitazone, was impaired in ob/ob;Shp−/− mice
both in lipogenesis and gluconeogenesis.
SHP deficiency affects TZD-responsive gene expression in
adipose tissue of ob/ob mice
White adipose tissue has been thought to be the major
site of TZD actions, as it is the only insulin-responsive
tissue with high expression of PPARγ compared to liver
and muscle [18]. Therefore, mRNA levels of genes re-
sponsive to TZDs in adipose tissue of control- and
troglitazone-treated ob/ob and ob/ob;Shp−/− mice were
analyzed by real-time quantitative PCR analysis (Figure 4).
Adipose tissue from ob/ob;Shp−/− mice showed an ap-
proximately 60% reduction in PPARγ2 expression, which
was not as dramatic as the nearly 90% reduction in the
liver (Figure 3A). CD36 and adiponectin expression was
not different between genotypes, whereas resistin de-
creased 35% in ob/ob;Shp−/− mice. Troglitazone induced
the expression of PPARγ2 and CD36 to a lesser extent in
ob/ob;Shp−/− mice than that in ob/ob mice, and failed to
induce expression of adiponectin and resistin in ob/
ob;Shp−/− mice, demonstrating that SHP is required for
full troglitazone responsiveness in adipose tissue.
SHP upregulates PPARγ2 expression in primary hepatocytes
To test the possibility that SHP might regulate PPARγ2
gene expression, the effects of SHP on the PPARγ2 gene
were examined by infecting mouse primary hepatocytes
with adenoviral vectors expressing SHP (Figure 5).
Transduction of cultured hepatocytes with SHP adeno-
virus decreased expression of CYP 7A1 mRNA, a known
SHP target gene, by 5.2 fold, while increasing PPARγ2
levels for 1.7 fold. These data indicate that SHP overex-
pression upregulates PPARγ2 expression in primary
hepatocytes.
Discussion
The therapeutic use of TZD drugs in the treatment of
insulin resistance and type 2 diabetes is now well estab-
lished [3-5]. TZDs act by increasing insulin sensitivity.
These drugs are high affinity ligands for the nuclear re-
ceptor PPARγ [9,10] and their antidiabetic effects are
thought to be mediated through PPARγ. Therefore, nor-
mal PPARγ expression levels, especially in the insulin-
responsive tissues, are critical for TZD actions. In this
study, we found that SHP deficiency causes downregula-
tion of PPARγ2 expression in liver and adipose tissue of
ob/ob mice, and these animals show diminished or abol-
ished responsiveness to the TZD troglitazone. It is re-
ported that mutations in SHP gene in humans are
associated with insulin resistance and mild obesity [27].
Our data suggest that the diabetic syndromes of subjects
with genetic mutations of SHP may not be improved by













































ob/ob ob/ob;Shp-/- ob/ob ob/ob;Shp-/-
Figure 4 SHP deficiency affects TZD-responsive gene expression in
adipose tissue of ob/ob mice. Results are adipose mRNA levels for
control (open bars) and troglitazone-treated (filled bars) mice after
2 weeks of treatment. Data are expressed as relative fold change
after normalized to 36B4 and are mean ± SEM (n = 4–5 per group).
By two-way ANOVA, the genotype and treatment effect is significant
(P < 0.05) for PPARγ2 and resistin (treatment effect for CD36, P = 0.06).
The genotype × treatment interaction is significant only for resistin. By
two-tailed t test, P < 0.05 for differences in adiponectin expression
between control and troglitazone-treated ob/ob mice.
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SHP mutation attenuates TZD actions, which makes
SHP a possible pharmacogenetic determinant of TZD
response.
The ob/ob;Shp−/− double mutant mice showed higher
blood glucose levels than ob/ob mice. This may be at-
tributed to abnormal glucose homeostasis in two tissues:
skeletal muscle and liver, which have the greatest direct
impact on plasma glucose levels. Whereas no difference
was observed between ob/ob and ob/ob;Shp−/− mice in
gene expression of glucose oxidation and glycogen syn-
thesis in muscle (data not shown), hepatic PEPCK
mRNA expression is enhanced in ob/ob;Shp−/− mice
compared to ob/ob mice, suggesting that increased glu-
coneogenesis may contribute to elevated glucose levels.
Moreover, the low insulin levels of ob/ob;Shp−/− mice
may indicate that pancreatic β cells fail to appropriately
compensate for insulin resistance by increasing insulin
secretion. It has been shown that independent of PPARγ
activation, SHP positively regulates glucose-stimulated
insulin secretion (GSIS) in β cells [40], which might be
impaired in ob/ob;Shp−/− mice.
The observation that ob/ob;Shp−/− mice exhibit worse
hyperglycemia and glucose intolerance than ob/ob mice
contrasts with our previous report [36]. In that study,
glucose and insulin levels were comparable in both ge-
notypes and loss of SHP was associated with improved
insulin sensitivity. One possible explanation is that the
age and gender of the mice in the two reports are not
exactly the same. The current studies focused solely on
male mice at the age of 10 weeks, or older after 2 weeks
of control or troglitazone treatment, whereas the prior
study used age- and sex-matched groups of younger
8 week old mice. The age of the ob/ob mice may be par-
ticularly important since blood glucose rises in this time
period before reaching a peak during 3–5 months of age.
Thus, it is possible that earlier beneficial effects of the
loss of SHP are not evident in these somewhat older
mice. Consistent with this, we have observed very similar
negative effects of the loss of SHP in long term studies of
wild type and Shp−/− mice fed a Western diet [39].
The loss of TZD responsiveness in the ob/ob;Shp−/−
mice is presumably a consequence of decreased PPARγ
expression. PPARγ1 expression in adipose tissue, liver
and muscle is not changed between genotypes, and
PPARγ2 expression in muscle is unaffected (Figure 3A
and data not shown). Thus, we conclude that loss of
SHP primarily affects PPARγ2 expression, which is the
dominant isoform in both adipose tissue and fatty liver
[41]. Although the effect on PPARγ2 expression was
strongest in the liver, a major SHP expressing tissue, de-
creased hepatic PPARγ2 cannot account for the loss of
antidiabetic effects of TZDs, since rosiglitazone im-
proved glucose homeostasis in liver-specific PPARγ
knockout mice in the ob/ob background [18]. Although
SHP is expressed at only low levels in adipose tissue
[33,38], white adipose is the primary target of TZD ac-
tions and PPARγ2 expression was significantly decreased
in ob/ob;Shp−/− adipose tissue. Consistent with this, the
induction of CD36 by troglitazone was decreased, and
the response of both adiponectin and resistin was lost in
the ob/ob;Shp−/− adipose tissue. Adiponectin promotes
fatty acid oxidation and insulin sensitivity in muscle and
liver, and the antidiabetic effects of a low dose of pioglit-
azone were lost in mice in which adiponectin deficiency
was introduced into the ob/ob background [42]. Thus,
the absence of its induction is likely a major factor in
the attenuated effects of troglitazone in the ob/ob;Shp−/−
mice. In contrast, elevated resistin has been proposed to
increase insulin resistance, and the repression of resistin
expression in normal mice by PPARγ agonists is thought
to enhance insulin sensitivity [43,44]. Thus, the inductive
effect of resistin by troglitazone in the ob/ob mice and
the loss of this response in the ob/ob;Shp−/− mice seems
inconsistent with the known resistin action. Similar in-
ductive effects of resistin by PPARγ activation have pre-





































Figure 5 SHP increases PPARγ2 expression in primary hepatocytes. Expression of SHP, CYP7A1 and PPARγ2 in adenovirus-mediated GFP- or
SHP-overexpressing hepatocytes by real-time quantitative PCR analysis. Hepatocytes were infected with green fluorescent protein (GFP) or SHP
adenovirus as indicated. Data are expressed as relative fold change after normalized to 36B4 and are mean ± SEM (n = 4–5 per group). *P < 0.001,
**P < 0.05, compared with GFP-infected cells.
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diabetic fatty rats [45], but this was not observed in an-
other study [42]. The basis for these discrepant mRNA
expression results, and also a substantial disconnect be-
tween resistin adipose mRNA and serum protein levels
in ob/ob mice [46], remains unresolved.
SHP is involved in the development of fatty liver by
regulating hepatic PPARγ2 and lipogenic genes. The in-
crease in PPARγ2 appears to be a general property of
steatotic liver in diet-induced and genetic obese models
[18-20,47,48]. Overexpression of PPARγ in a hepatic cell
line leads to marked lipid accumulation [49], as does
overexpression in PPARα null livers [50]. Thus, SHP de-
ficiency reduced the elevated levels of PPARγ2 and lipo-
genic genes in ob/ob liver, resulting in the improvement
of fatty liver. Additional effects on other pathways may
also contribute to the decreased triglyceride accumula-
tion [36].
Recent studies have started to shed light on the mo-
lecular basis for the transcriptional regulation of PPARγ
by SHP. Renga et al. described that FXR binds to the
PPARγ promoter and activates its transcription via the
recruitment of SHP in hepatic stellate cells [51]. Whereas
Kim et al. identified a novel transcriptional cascade linking
RAR/SHP signals with PPARγ2 expression through hairy
and enhancer of split 6 (Hes6) in hepatocytes [52]. This
transcriptional regulatory pathway controls hepatic lipid
metabolism and provides a potential therapeutic entry
point for NAFLD. These studies indicate that SHP appears
to upregulate PPARγ expression by diverse mechanisms in
different cell types.
Conclusions
In summary, our results demonstrate that the antidia-
betic and hypolipidemic actions of TZDs require the
presence of SHP, likely due to the downregulation of
PPARγ2 expression in the adipose tissue and liver of ob/
ob;Shp−/− mice. Thus, genetic or pharmacologic modula-
tion of SHP activity could alter the efficacy of TZD anti-
diabetic actions.
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